Concise review: Genomic instability in human stem cells: Current status and future challenges

Stem Cells

Volumn 32, Issue 11, 2014, Pages 2824-2832

  Oliveira, Pedro H ^a   Da Silva, Cláudia Lobato ^b   Cabral, Joaquim M S ^b  

^a CNRS   (France)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

Adult stem cells; Chromosomal aberrations; Clinical translation; Embryonic stem cells; Induced pluripotent stem cells

Indexed keywords

ANIMALS; CELL DIFFERENTIATION; CHROMOSOME ABERRATIONS; CYTOLOGY; GENETICS; GENOMIC INSTABILITY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; METHODS; STEM CELL TRANSPLANTATION; TELOMERE;

ANIMALS; CELL DIFFERENTIATION; CHROMOSOME ABERRATIONS; GENOMIC INSTABILITY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; TELOMERE;

EID: 84907906057     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1796     Document Type: Article

References (108)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
2. Takahashi K, Yamanaka S,. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
3. Ji J, Ng SH, Sharma V, et al. Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells. Stem Cells 2012; 30435-440.
4. EMA. Reflection paper on stem cell-based medicinal products. Committee for Advanced Therapies (CAT)-European Medicines Agency 2011.
5. International Stem Cell Banking Initiative. Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes. Stem Cell Rev 2009; 5: 301-314.
6. Lysaght T, Campbell AV,. Regulating autologous adult stem cells: The FDA steps up. Cell Stem Cell 2011; 9: 393-396.
7. Cyranoski D,. Strange lesions after stem-cell therapy. Nature 2010; 465: 997.
8. ISCN 2013. An International System for Human Cytogenetic Nomenclature. Basel: S Karger; 2013.
9. Muntion S, Sanchez-Guijo FM, Carrancio S, et al. Optimisation of mesenchymal stromal cells karyotyping analysis: Implications for clinical use. Transfus Med 2012; 22: 122-127.
10. Bauman JG, Wiegant J, Borst P, et al. A new method for fluorescence microscopical localization of specific DNA sequences by in situ hybridization of fluorochromelabelled RNA. Exp Cell Res 1980; 128: 485-490.
11. Hu L, Ru K, Zhang L, et al. Fluorescence in situ hybridization (FISH): An increasingly demanded tool for biomarker research and personalized medicine. Biomarker Res 2014; 2: 3.
12. Schrock E, du Manoir S, Veldman T, et al. Multicolor spectral karyotyping of human chromosomes. Science 1996; 273: 494-497.
13. Speicher MR, Gwyn Ballard S, Ward DC,. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 1996; 12: 368-375.
14. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-821.
15. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20: 207-211.
16. Solinas-Toldo S, Lampel S, Stilgenbauer S, et al. Matrix-based comparative genomic hybridization: Biochips to screen for genomic imbalances. Genes, Chromosomes Cancer 1997; 20: 399-407.
17. Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci USA 2004; 101: 17765-17770.
18. Carter NP,. Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet 2007; 39: S16-S21.
19. Le Scouarnec S, Gribble SM,. Characterising chromosome rearrangements: Recent technical advances in molecular cytogenetics. Heredity (Edinb) 2012; 108: 75-85.
20. Baker DE, Harrison NJ, Maltby E, et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol 2007; 25: 207-215.
21. Lefort N, Feyeux M, Bas C, et al. Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat Biotechnol 2008; 26: 1364-1366.
22. Narva E, Autio R, Rahkonen N, et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol 2010; 28: 371-377.
23. Draper JS, Smith K, Gokhale P, et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol 2004; 22: 53-54.
24. Catalina P, Montes R, Ligero G, et al. Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties? Mol Cancer 2008; 7: 76.
25. Mitalipova MM, Rao RR, Hoyer DM, et al. Preserving the genetic integrity of human embryonic stem cells. Nat Biotechnol 2005; 23: 19-20.
26. Moon SH, Kim JS, Park SJ, et al. Effect of chromosome instability on the maintenance and differentiation of human embryonic stem cells in vitro and in vivo. Stem Cell Res 2011; 6: 50-59.
27. International Stem Cell I, Amps K, Andrews PW, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol 2011; 29: 1132-1144.
28. Spits C, Mateizel I, Geens M, et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat Biotechnol 2008; 26: 1361-1363.
29. Maitra A, Arking DE, Shivapurkar N, et al. Genomic alterations in cultured human embryonic stem cells. Nat Genet 2005; 37: 1099-1103.
30. Buzzard JJ, Gough NM, Crook JM, et al. Karyotype of human ES cells during extended culture. Nat Biotechnol 2004; 22: 381-382.
31. Nguyen HT, Geens M, Mertzanidou A, et al. Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL. Mol Hum Reprod 2014; 20: 168-177.
32. Inzunza J, Sahlen S, Holmberg K, et al. Comparative genomic hybridization and karyotyping of human embryonic stem cells reveals the occurrence of an isodicentric X chromosome after long-term cultivation. Mol Hum Reprod 2004; 10: 461-466.
33. The International Stem Cell Initiative, Amps K, Andrews PW, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol 2011; 29: 1132-1144.
34. Avery S, Hirst AJ, Baker D, et al. BCL-XL mediates the strong selective advantage of a 20q11.21 amplification commonly found in human embryonic stem cell cultures. Stem Cell Rep 2013; 1: 379-386.
35. Olejniczak ET, Van Sant C, Anderson MG, et al. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res 2007; 5: 331-339.
36. Mackinnon RN, Selan C, Wall M, et al. The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion. Genes, Chromosomes Cancer 2010; 49: 998-1013.
37. Peterson SE, Westra JW, Rehen SK, et al. Normal human pluripotent stem cell lines exhibit pervasive mosaic aneuploidy. PLoS One 2011; 6: e23018.
38. Wu H, Kim KJ, Mehta K, et al. Copy number variant analysis of human embryonic stem cells. Stem Cells 2008; 26: 1484-1489.
39. Laurent LC, Ulitsky I, Slavin I, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8: 106-118.
40. Lefort N, Perrier AL, Laabi Y, et al. Human embryonic stem cells and genomic instability. Regen Med 2009; 4: 899-909.
41. Imreh MP, Gertow K, Cedervall J, et al. In vitro culture conditions favoring selection of chromosomal abnormalities in human ES cells. J Cell Biochem 2006; 99: 508-516.
42. Forsyth NR, Musio A, Vezzoni P, et al. Physiologic oxygen enhances human embryonic stem cell clonal recovery and reduces chromosomal abnormalities. Cloning Stem Cells 2006; 8: 16-23.
43. Oh SK, Chen AK, Mok Y, et al. Long-term microcarrier suspension cultures of human embryonic stem cells. Stem Cell Res 2009; 2: 219-230.
44. Olmer R, Haase A, Merkert S, et al. Long term expansion of undifferentiated human iPS and ES cells in suspension culture using a defined medium. Stem Cell Res 2010; 5: 51-64.
45. Herszfeld D, Wolvetang E, Langton-Bunker E, et al. CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat Biotechnol 2006; 24: 351-357.
46. Mateizel I, Spits C, Verloes A, et al. Characterization of CD30 expression in human embryonic stem cell lines cultured in serum-free media and passaged mechanically. Hum Reprod 2009; 24: 2477-2489.
47. Chung TL, Turner JP, Thaker NY, et al. Ascorbate promotes epigenetic activation of CD30 in human embryonic stem cells. Stem Cells 2010; 28: 1782-1793.
48. Van Haute L, Spits C, Geens M, et al. Human embryonic stem cells commonly display large mitochondrial DNA deletions. Nat Biotechnol 2013; 31: 20-23.
49. Advanced Cell Technology. Safety and tolerability of sub-retinal transplantation of human embryonic stem cell derived retinal pigmented epithelial (hESC-RPE) cells in patients with stargardt's macular dystrophy (SMD). Available at: http://clinicaltrials.gov/ct2/show/NCT01469832. Accessed 2014.
50. Geron Corporation. Safety Study of GRNOPC1 in Spinal Cord Injury. Available at: http://clinicaltrials.gov/ct2/show/NCT01217008. Accessed 2014.
51. Willyard C,. Stem cells a time to heal. Nature 2013; 503: S4-S6.
52. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
53. Taapken SM, Nisler BS, Newton MA, et al. Karotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. Nat Biotechnol 2011; 29: 313-314.
54. Martins-Taylor K, Nisler BS, Taapken SM, et al. Recurrent copy number variations in human induced pluripotent stem cells. Nat Biotechnol 2011; 29: 488-491.
55. Mayshar Y, Ben-David U, Lavon N, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010; 7: 521-531.
56. Hussein SM, Batada NN, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471: 58-62.
57. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-67.
58. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells 2010; 28: 1568-1570.
59. Luo L, Kawakatsu M, Guo CW, et al. Effects of antioxidants on the quality and genomic stability of induced pluripotent stem cells. Sci Rep 2014; 4: 3779.
60. Ji J, Sharma V, Qi S, et al. Antioxidant supplementation reduces genomic aberrations in human induced pluripotent stem cells. Stem Cell Rep 2014; 2: 44-51.
61. Prigione A, Lichtner B, Kuhl H, et al. Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic reprogramming. Stem Cells 2011; 29: 1338-1348.
62. Prigione A, Hossini AM, Lichtner B, et al. Mitochondrial-associated cell death mechanisms are reset to an embryonic-like state in aged donor-derived iPS cells harboring chromosomal aberrations. PLoS One 2011; 6: e27352.
63. Kim K, Zhao R, Doi A, et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol 2011; 29: 1117-1119.
64. Carey BW, Markoulaki S, Hanna JH, et al. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell 2011; 9: 588-598.
65. Pick M, Stelzer Y, Bar-Nur O, et al. Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells. Stem Cells 2009; 27: 2686-2690.
66. Ohm JE, Mali P, Van Neste L, et al. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res 2010; 70: 7662-7673.
67. Zhou YY, Zeng F,. Integration-free methods for generating induced pluripotent stem cells. Genomics, Proteomics Bioinformatics 2013; 11: 284-287.
68. Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013; 341: 651-654.
69. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/results?term=%22mesenchymal+stem+cells%22+AND+human&Search=Search. Accessed 2014.
70. Bonab MM, Alimoghaddam K, Talebian F, et al. Aging of mesenchymal stem cell in vitro. BMC Cell Biol 2006; 7: 14.
71. Baxter MA, Wynn RF, Jowitt SN, et al. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004; 22: 675-682.
72. Sensebe L, Bourin P, Tarte K,. Good manufacturing practices production of mesenchymal stem/stromal cells. Human Gene Ther 2011; 22: 19-26.
73. Ben-David U, Mayshar Y, Benvenisty N,. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell. 2011; 9: 97-102.
74. Sareen D, McMillan E, Ebert AD, et al. Chromosome 7 and 19 trisomy in cultured human neural progenitor cells. PLoS One 2009; 4: e7630.
75. Tarte K, Gaillard J, Lataillade JJ, et al. Clinical-grade production of human mesenchymal stromal cells: Occurrence of aneuploidy without transformation. Blood 2010; 115: 1549-1553.
76. Rubio D, Garcia S, Paz MF, et al. Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS One 2008; 3: e1398.
77. Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67: 9142-9149.
78. Wang Y, Zhang Z, Chi Y, et al. Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malignant transformation. Cell Death Dis 2013; 4: e950.
79. Wu W, He Q, Li X, et al. Long-term cultured human neural stem cells undergo spontaneous transformation to tumor-initiating cells. Int J Biol Sci 2011; 7: 892-901.
80. Varela C, Denis JA, Polentes J, et al. Recurrent genomic instability of chromosome 1q in neural derivatives of human embryonic stem cells. J Clin Invest 2012; 122: 569-574.
81. Meza-Zepeda LA, Noer A, Dahl JA, et al. High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. J Cell Mol Med 2008; 12: 553-563.
82. Estrada JC, Torres Y, Benguria A, et al. Human mesenchymal stem cell-replicative senescence and oxidative stress are closely linked to aneuploidy. Cell Death Dis 2013; 4: e691.
83. Ge J, Cai H, Tan WS,. Chromosomal stability during ex vivo expansion of UCB CD34(+) cells. Cell Prolif 2011; 44: 550-557.
84. Corselli M, Parodi A, Mogni M, et al. Clinical scale ex vivo expansion of cord blood-derived outgrowth endothelial progenitor cells is associated with high incidence of karyotype aberrations. Exp Hematol 2008; 36: 340-349.
85. Rossi DJ, Bryder D, Seita J, et al. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 2007; 447: 725-729.
86. Rube CE, Fricke A, Widmann TA, et al. Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. PLoS One 2011; 6: e17487.
87. Ueyama H, Horibe T, Hinotsu S, et al. Chromosomal variability of human mesenchymal stem cells cultured under hypoxic conditions. J Cell Mol Med 2012; 16: 72-82.
88. Zhou S, Greenberger JS, Epperly MW, et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008; 7: 335-343.
89. Holzwarth C, Vaegler M, Gieseke F, et al. Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. BMC Cell Biol 2010; 11: 11.
90. Estrada JC, Albo C, Benguria A, et al. Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. Cell Death Differ 2012; 19: 743-755.
91. Li TS, Marban E,. Physiological levels of reactive oxygen species are required to maintain genomic stability in stem cells. Stem Cells 2010; 28: 1178-1185.
92. Tsai CC, Chen YJ, Yew TL, et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 2011; 117: 459-469.
93. Rodriguez-Jimenez FJ, Moreno-Manzano V, Lucas-Dominguez R, et al. Hypoxia causes downregulation of mismatch repair system and genomic instability in stem cells. Stem Cells 2008; 26: 2052-2062.
94. Oliveira PH, Boura JS, Abecasis MM et al. Impact of hypoxia and long-term cultivation on the genomic stability and mitochondrial performance of ex-vivo expanded human stem/stromal cells Stem Cell Res 2012; 9: 225-236.
95. Zimmermann S, Voss M, Kaiser S, et al. Lack of telomerase activity in human mesenchymal stem cells. Leukemia 2003; 17: 1146-1149.
96. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
97. Ho JH, Chen YF, Ma WH, et al. Cell contact accelerates replicative senescence of human mesenchymal stem cells independent of telomere shortening and p53 activation: Roles of Ras and oxidative stress. Cell Transplant 2011; 20: 1209-1220.
98. Fischer U, Keller A, Voss M, et al. Genome-wide gene amplification during differentiation of neural progenitor cells in vitro. PloS One 2012; 7: e37422.
99. Mali P, Cheng L,. Concise review: Human cell engineering: Cellular reprogramming and genome editing. Stem Cells 2012; 30: 75-81.
100. Ben-David U, Mayshar Y, Benvenisty N,. Virtual karyotyping of pluripotent stem cells on the basis of their global gene expression profiles. Nat Protoc 2013; 8: 989-997.
101. Baerlocher GM, Vulto I, de Jong G, et al. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc 2006; 1: 2365-2376.
102. Gil ME, Coetzer TL,. Real-time quantitative PCR of telomere length. Mol Biotechnol 2004; 27: 169-172.
103. O'Callaghan N, Dhillon V, Thomas P, et al. A quantitative real-time PCR method for absolute telomere length. Biotechniques 2008; 44: 807-809.
104. Yasuda T, Ueno T, Fukumura K, et al. Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia 2014; 28: 426-428.
105. Editorial. Identity crisis. Nature 2009; 457: 935-936.
106. Chatterjee R,. Cell biology. Cases of mistaken identity. Science 2007; 315: 928-931.
107. Hughes P, Marshall D, Reid Y, et al. The costs of using unauthenticated, over-passaged cell lines: How much more data do we need? Biotechniques 2007; 43: 575, 577-578, 581-572 passim.
108. Torsvik A, Rosland GV, Svendsen A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: Putting the research field on track-Letter. Cancer Res 2010; 70: 6393-6396.